Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 123157002 | 12315700 | 2 | F | 20160303 | 20160824 | 20160428 | 20160901 | EXP | FR-ANSM-NT20160469 | FR-MYLANLABS-2016M1017462 | MYLAN | 0.00 | Y | 0.00000 | 20160901 | OT | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 123157002 | 12315700 | 1 | PS | FONDAPARINUX | FONDAPARINUX | 1 | Subcutaneous | 2.5 MG, QD | 45 | MG | Y | 21345 | 2.5 | MG | INJECTION | QD | |||
| 123157002 | 12315700 | 2 | SS | PLAVIX | CLOPIDOGREL BISULFATE | 1 | Oral | 75 MG, QD | Y | 0 | 75 | MG | FILM-COATED TABLET | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 123157002 | 12315700 | 1 | Thrombophlebitis |
| 123157002 | 12315700 | 2 | Acute coronary syndrome |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 123157002 | 12315700 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 123157002 | 12315700 | Abdominal wall haematoma | |
| 123157002 | 12315700 | Anaemia | |
| 123157002 | 12315700 | Off label use |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 123157002 | 12315700 | 1 | 20160303 | 20160320 | 0 | |
| 123157002 | 12315700 | 2 | 201103 | 20160326 | 0 |